Survival rates for childhood leukemia are improving thanks to new treatments. Acute lymphoblastic leukemia has the highest survival among all pediatric cancers, 80-85 percent. Seattle Children’s ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. The research focused on 2 primary ...

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

June 11, 2009 (Berlin, Germany) — The novel CD20 monoclonal antibody ofatumumab (Arzerra) has demonstrated superior response rates in 2 challenging groups of chronic lymphocytic leukemia (CLL) ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia treated at specialized cancer centers have significantly higher survival rates than their peers who are not ...

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA®) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...